Literature DB >> 17887752

Biochemical evaluation of a 108-member deglycobleomycin library: viability of a selection strategy for identifying bleomycin analogues with altered properties.

Qian Ma1, Zhidong Xu, Benjamin R Schroeder, Wenyue Sun, Fang Wei, Shigeki Hashimoto, Kazuhide Konishi, Christopher J Leitheiser, Sidney M Hecht.   

Abstract

The bleomycins (BLMs) are clinically used glycopeptide antitumor antibiotics that have been shown to mediate the sequence-selective oxidative damage of both DNA and RNA. Previously, we described the solid-phase synthesis of a library of 108 unique analogues of deglycoBLM A6, a congener that cleaves DNA analogously to BLM itself. Each member of the library was assayed for its ability to effect single- and double-strand nicking of duplex DNA, sequence-selective DNA cleavage, and RNA cleavage in the presence and absence of a metal ion cofactor. All of the analogues tested were found to mediate concentration-dependent plasmid DNA relaxation to some extent, and a number exhibited double-strand cleavage with an efficiency comparable to or greater than deglycoBLM A6. Further, some analogues having altered linker and metal-binding domains mediated altered sequence-selective cleavage, and a few were found to cleave a tRNA3Lys transcript both in the presence and in the absence of a metal cofactor. The results provide insights into structural elements within BLM that control DNA and RNA cleavage. The present study also permits inferences to be drawn regarding the practicality of a selection strategy for the solid-phase construction and evaluation of large libraries of BLM analogues having altered properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17887752     DOI: 10.1021/ja0722729

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  5 in total

1.  Functional characterization of tlmH in Streptoalloteichus hindustanus E465-94 ATCC 31158 unveiling new insight into tallysomycin biosynthesis and affording a novel bleomycin analog.

Authors:  Meifeng Tao; Liyan Wang; Evelyn Wendt-Pienkowski; Ningning Zhang; Dong Yang; Ute Galm; Jane M Coughlin; Zhinan Xu; Ben Shen
Journal:  Mol Biosyst       Date:  2009-12-01

2.  A designer bleomycin with significantly improved DNA cleavage activity.

Authors:  Sheng-Xiong Huang; Zhiyang Feng; Liyan Wang; Ute Galm; Evelyn Wendt-Pienkowski; Dong Yang; Meifeng Tao; Jane M Coughlin; Yanwen Duan; Ben Shen
Journal:  J Am Chem Soc       Date:  2012-08-06       Impact factor: 15.419

Review 3.  Small molecule recognition of disease-relevant RNA structures.

Authors:  Samantha M Meyer; Christopher C Williams; Yoshihiro Akahori; Toru Tanaka; Haruo Aikawa; Yuquan Tong; Jessica L Childs-Disney; Matthew D Disney
Journal:  Chem Soc Rev       Date:  2020-10-05       Impact factor: 54.564

4.  Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype.

Authors:  Yue Li; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2018-10-30       Impact factor: 5.100

Review 5.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.